We caught up with Tomáš Hanke (University of Oxford, Oxford, UK) to discuss T-cell vaccine strategies for the treatment of people with HIV-1 infection.
His abstract entitled: ‘Refocusing T cell responses with therapeutic vaccination strategies’ (SY09.03) was presented at the HIVR4P Virtual Conference 2021, 04 February 2021.
Part 2 of our discussion can be viewed here.
Questions:
- What is the rationale for developing T-cell vaccines for the treatment of people with HIV-1 infection? (0:19)
- What have been the greatest challenges to producing an effective and safe vaccine? (1:23)
- What vaccine strategies have proved most successful to date? (2:28)
Disclosures: Tomáš Hanke is a QA coinventor on a patent protecting the use of the conserved mosaic vaccines.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the HIVR4P Virtual Conference 2021.
